Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | F2R | P25116 | 8/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4340538 | 0.77 | KMT2A (0.58) | KMT2AMEN1F2RRECQL | |
| Bromide SCHEMBL10529434 | 0.76 | POLB (0.52) | KMT2AMEN1RECQLLMNAPOLB | |
| Bromide SCHEMBL3848624 | 0.76 | ALDH1A1 (0.57) | KMT2AMEN1ALOX5PTGS1PTGS2 | |
| Bromide SCHEMBL10528517 | 0.76 | KMT2A (0.42) | KMT2AMEN1RECQLLMNAPOLB | |
| Bromide SCHEMBL3854850 | 0.75 | KMT2A (0.53) | KMT2AMEN1ALOX5PTGS1PTGS2 | |
| Bromide SCHEMBL3844583 | 0.75 | KMT2A (0.67) | KMT2AMEN1RECQLLMNAPOLB | |
| SCHEMBL6938305 | 0.74 | ALDH1A1 (0.55) | KMT2AMEN1ALOX5PTGS1PTGS2 | |
| Bromide SCHEMBL10528569 | 0.73 | POLB (0.67) | KMT2AMEN1RECQLLMNAPOLB | |
| Bromide SCHEMBL10528545 | 0.73 | POLB (0.49) | KMT2AMEN1RECQLLMNAPOLB | |
| SCHEMBL16624840 | 0.73 | KMT2A (0.64) | KMT2AMEN1RECQLLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1353669-B1 | METHOD FOR TREATING GLAUCOMA | ALTEON INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | SYNVISTA THERAPEUTICS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | ALTEON, INC. | 2003-09-18 | — | — | US | disclosed |
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1327887-A2 | Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products | Alteon, Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020193412-A1 | Compounds and compositions for treating tissue ischemia | TRACEY KEVIN J (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020192842-A1 | Method of treating certain indications associated with hyperglycemia | CERAMI ANTHONY (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6391899-B1 | STROKE THERAPY; CARDIOVASCULAR DISORDERS | North Shore—Long Island Jewish Research Institute | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193412-A1 | Compounds and compositions for treating tissue ischemia | TNNI3, ABAT, ALDH7A1 | KMT2A 3340/4885MEN1 4550/4885ALOX5 711/4885 |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | KMT2A 4599/4885MEN1 1999/4885ALOX5 294/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | KMT2A 4535/4885MEN1 1815/4885ALOX5 1110/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | KMT2A 4545/4885MEN1 2481/4885ALOX5 259/4885 |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, COL2A1 | KMT2A 4051/4885MEN1 494/4885ALOX5 2213/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | KMT2A 4493/4885MEN1 3331/4885ALOX5 60/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | KMT2A 4326/4885MEN1 2134/4885ALOX5 470/4885 |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, EPX | KMT2A 4075/4885MEN1 515/4885ALOX5 1659/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | KMT2A 4520/4885MEN1 3327/4885ALOX5 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.